A
Altimmune D
D
ALT
2.95000
USD
0.06
(2.08%)
قبل الجلسة·2.96000USD+0.01000(+0.34%)
حجم التداول
106,748
الربح لكل سهم
-1
العائد الربحي
-
P/E
-4
حجم السوق
573,827,218
العنوان: Altimmune
القطاع: الرعاية الصحية
الصناعة: Biotechnology
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
